Literature DB >> 12736380

Endogenous surfactant metabolism in newborn infants with and without respiratory failure.

Kajsa Bohlin1, Assaad Merchak, Kimberly Spence, Bruce W Patterson, Aaron Hamvas.   

Abstract

Studies using stable isotopically labeled glucose and palmitate as precursors of pulmonary surfactant synthesis have demonstrated slow surfactant turnover in premature infants with respiratory distress syndrome (RDS). However, only limited data about surfactant turnover are available for term infants. Because acetate is a direct precursor of de novo synthesized surfactant fatty acid, we measured [1-13C1]acetate incorporation into surfactant of term infants without respiratory dysfunction (control group), preterm infants with RDS, and term infants with primary respiratory failure to determine whether stable isotopically labeled acetate would yield similar results to previous studies of preterm infants with RDS and, furthermore, would distinguish normal from abnormal surfactant turnover. Despite similar amounts of phospholipids and acetate precursor enrichment, the control group had higher fractional synthetic rate and shorter half-life of clearance than preterm infants with RDS, (fractional synthetic rate, 15.4 +/- 2.4 versus 2.2 +/- 0.4%/d, p < 0.001; half-life of clearance, 27 +/- 3 versus 105 +/- 11 h, p < 0.001). Term infants with severe respiratory failure had a lower fractional synthetic rate than those with mild disease (2.9 +/- 0.6 versus 13.8 +/- 3.5%/d, p = 0.014) and a reduced amount of phospholipids recovered from tracheal aspirates (54 +/- 17 versus 300 +/- 28 nmol, severe versus mild disease, respectively, p < 0.001). The amount of phospholipids in tracheal aspirates correlated inversely with disease severity, (r = -0.75, p = 0.01). We conclude that normal surfactant turnover in term infants is faster than in preterm infants with RDS. Surfactant turnover in term infants with severe respiratory failure is similar to that of preterm infants with RDS, suggesting either delayed maturity of the surfactant system or disruption from the underlying disease process.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12736380     DOI: 10.1203/01.PDR.0000075084.56255.E0

Source DB:  PubMed          Journal:  Pediatr Res        ISSN: 0031-3998            Impact factor:   3.756


  4 in total

Review 1.  Cellular Metabolism in Lung Health and Disease.

Authors:  Gang Liu; Ross Summer
Journal:  Annu Rev Physiol       Date:  2018-11-28       Impact factor: 19.318

2.  Metabolic precursors of surfactant disaturated-phosphatidylcholine in preterms with respiratory distress.

Authors:  Paola E Cogo; Carlo Ori; Manuela Simonato; Giovanna Verlato; Ilena Isak; Aaron Hamvas; Virgilio P Carnielli
Journal:  J Lipid Res       Date:  2009-05-27       Impact factor: 5.922

3.  Decreased surfactant phosphatidylcholine synthesis in neonates with congenital diaphragmatic hernia during extracorporeal membrane oxygenation.

Authors:  Daphne J Janssen; Luc J Zimmermann; Paola Cogo; Aaron Hamvas; Kajsa Bohlin; Ingrid H Luijendijk; Darcos Wattimena; Virgilio P Carnielli; Dick Tibboel
Journal:  Intensive Care Med       Date:  2009-07-07       Impact factor: 17.440

4.  Commentary on the Truncated Splice Variant of the GM-CSF Receptor Beta-Chain in Peripheral Blood Serves as Severity Biomarker of Respiratory Failure in Newborns.

Authors:  Jeffrey A Whitsett; Alan H Jobe
Journal:  Neonatology       Date:  2021-03-19       Impact factor: 4.035

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.